Boster Biological Technology advances biotechnology research with its cutting-edge multiplex ELISA service, delivering ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...

primarily revolving around the promising commercial prospects of Cytokinetics’ drug pipeline. The company’s strategic focus is on aficamten, which is anticipated to gain approval and be ...

The company — on track to secure U.S. approval in September for a drug to treat a serious heart condition — is not for sale. With more than $1 billion raised last year, Blum is preparing ...

However, significant knowledge gaps exist in the comprehension of the mechanisms of action of these drugs and determination of the optimal ... It comprises inflammatory cytokines, growth and ...

He, H.J., Cen, X.H., Liang, Y.J., Zhong, J.M., Deng, J.H. and Jiang, Y.J. (2025) Progress in the Regulation of Lipid Metabolism by the Orphan Nuclear Receptor Nur77. Journal of Biosciences and ...

In the realm of medicine, recombinant cytokines are increasingly being utilized as therapeutic agents for a variety of diseases, including cancers, infections, and hematopoietic disorders. These ...

Patients treated with aficamten showed a mean increase of 1.74 mL/kg/min in peak oxygen uptake (pVO2) compared to placebo, which is considered superior to results seen with competing drugs in similar ...

Cytokinetics recently announced that the FDA has accepted the company’s new drug application (NDA) for lead pipeline candidate, aficamten. Aficamten is a next-in-class cardiac myosin inhibitor.

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has accepted the company's New ...